hormone therapy
- Generic Name
- hormone therapy
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
- Conditions
- Metastatic Tumor
- Interventions
- Radiation: Palliative RadiotherapyDrug: ChemotherapyDrug: ImmunotherapyDrug: Targeted Systemic TherapyOther: ObservationRadiation: Stereotactic Ablative RadiotherapyProcedure: SurgeryOther: Radiofrequency Therapy (RFA)Radiation: Fractionated Radiation
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- David Palma
- Target Recruit Count
- 180
- Registration Number
- NCT05717166
- Locations
- 🇨🇦
BC Cancer - Vancouver, Vancouver, British Columbia, Canada
🇨🇦Centre Hospitalier de l'Université de Montréal-CHUM, Montréal, Quebec, Canada
🇨🇦BC Cancer - Centre for the North, Prince George, British Columbia, Canada
Immediate Curative Vs Conservative Treatment in Older Men with M0, High-risk Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Sven Löffeler
- Target Recruit Count
- 980
- Registration Number
- NCT05448547
- Locations
- 🇫🇮
Helsinki University Hospital, Helsinki, Finland
🇫🇮Turku University Hospital, Turku, Finland
🇳🇴Telemark Hospital Trust, Skien, Telemark, Norway
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer With a Isolated Brain Progression
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 53
- Registration Number
- NCT05041842
- Locations
- 🇫🇷
Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France
🇫🇷Centre Francois Baclesse, Caen, France
🇫🇷Centre Georges François Leclerc, Dijon, France
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
- Conditions
- Stage IIIC Prostate Cancer AJCC v8Stage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 102
- Registration Number
- NCT04915508
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Radiation: SBRT
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 60
- Registration Number
- NCT04619069
- Locations
- 🇨🇦
Odette Cancer Centre, Toronto, Ontario, Canada
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- Conditions
- Prostate AdenocarcinomaStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Bone ScanProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Radiation Therapy
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 586
- Registration Number
- NCT04134260
- Locations
- 🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Kaiser Permanente-Anaheim, Anaheim, California, United States
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
- Conditions
- HER2-positive Early Breast Cancer
- Interventions
- Procedure: SurgeryRadiation: Post-Operative Radiotherapy
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT04024462
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, China
🇨🇳West China Hospital, Sichuan University, Chengdu, China
🇨🇳The 900th Hospital of PLA joint service support force, Fuzhou, China
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
- Conditions
- Early Breast Cancer
- Interventions
- Drug: FDC of Pertuzumab and Trastuzumab SCProcedure: SurgeryRadiation: Post-operative Radiotherapy
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 500
- Registration Number
- NCT03493854
- Locations
- 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
🇯🇵St. Luke's International Hospital, Tokyo, Japan
🇧🇪Institut Jules Bordet, Anderlecht, Belgium
The Efficacy of G-CSF Against Adhesion Reformation After Hysteroscopic Adhesiolysis
- Conditions
- Intrauterine Adhesion
- Interventions
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT02855632
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT02366130
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.